Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Recurrence 6Neoplasm Metastasis 4Lymphoma, T-Cell, Peripheral 4Lymphoma, T-Cell 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell 2Lymphoma 2Lung Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Thyroid Diseases 1Smoking 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Papillomavirus Infections 1Papilloma 1Pancreatic Neoplasms 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Laryngeal Diseases 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Carboplatin 30Cisplatin 23pembrolizumab 22Paclitaxel 21Pemetrexed 20Gemcitabine 10osimertinib 9durvalumab 9Nivolumab 9130-nm albumin-bound paclitaxel 8Sunitinib 7Sorafenib 7Fluorouracil 7Everolimus 7Docetaxel 7Axitinib 7Cetuximab 6epothilone B 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5volociximab 4trebananib 4reolysin 4catumaxomab 4cabozantinib 4atezolizumab 4Radiotherapy 4Ipilimumab 4vosaroxin 3liposomal doxorubicin 3lenvatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma × Vitamin B 12 × Clear all
NCT00722553 2019-12-17

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Acrotech Biopharma Inc.

Phase 2 Completed
30 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡